Furthermore, the presence of PV in the BARD1 gene introduces the possibility of incorporating PARP inhibitors (Poly (ADP-ribose) polymerase inhibitors) as therapeutic agents, patients benefit from this treatment that originally targeted other forms of HBOC with pathogenic mutations in genes such as BRCA1 and PALB2 [43]. Here, PARP1 is linked to acquired polycythemia vera.